GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
A

Al-Razi Medical Company SJSC 9572.SR · SAR

Health Care · Tadawul · 🇸🇦 Saudi Arabia

Compare

22.80

—

Close of 9 Nov 2026, in SAR

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

At a glance

Figures in SAR, from our data supplier.

FY2025

Revenue

SAR 74.4m

FY2021FY2025

Net income

SAR 819,462

FY2021FY2025

Free cash flow

SAR 3.8m

FY2021FY2025

Shareholders' equity

SAR 23.5m

FY2021FY2025

Income statement

Fiscal years

FY2025FY2024FY2023FY2022FY2021
RevenueSAR 74.4mSAR 61.4mSAR 61.3mSAR 52.4mSAR 45.2m
Gross profitSAR 19.3mSAR 16.6mSAR 14.1mSAR 13.6mSAR 11.2m
Operating incomeSAR 1.6mSAR 434,609SAR 1.8mSAR 2.9mSAR 2.6m
Net incomeSAR 819,462SAR 175,867SAR 685,968SAR 2.0mSAR 2.2m
Diluted earnings per share0.540.120.451.331.43

Balance sheet

At each fiscal year end

FY2025FY2024FY2023FY2022FY2021
Total assetsSAR 53.3mSAR 40.9mSAR 45.4mSAR 42.8mSAR 40.0m
Cash and short-term investments—SAR 767,107SAR 700,398SAR 1.3mSAR 7.6m
Total liabilitiesSAR 29.8mSAR 18.2mSAR 23.0mSAR 19.2mSAR 15.8m
DebtSAR 1.0mSAR 8.6mSAR 10.7mSAR 7.7mSAR 6.6m
Shareholders' equitySAR 23.5mSAR 22.6mSAR 22.4mSAR 23.6mSAR 24.2m
Shares outstanding2m2m2m2m2m

Cash flow

Fiscal years

FY2025FY2024FY2023FY2022FY2021
Cash from operationsSAR 5.8mSAR 5.0mSAR 5.8mSAR 2.0m−SAR 1.7m
Capital spending−SAR 2.0m−SAR 3.9m−SAR 4.8m−SAR 2.9m−SAR 1.2m
Free cash flowSAR 3.8mSAR 1.1mSAR 996,817−SAR 892,006−SAR 2.9m
Dividends paid——−SAR 2.4m−SAR 1.9m—

Latest quarters

By quarter end

Dec 2025Jun 2025Dec 2024Jun 2024Dec 2023Jun 2023Dec 2022Jun 2022
RevenueSAR 40.4mSAR 34.0mSAR 30.1mSAR 31.2mSAR 30.8mSAR 30.5mSAR 14.2mSAR 38.2m
Gross profitSAR 10.2mSAR 9.1mSAR 8.2mSAR 8.2mSAR 8.2mSAR 9.1mSAR 4.4mSAR 9.1m
Operating incomeSAR 10.2mSAR 601,872SAR 206,650SAR 227,960SAR 415,586SAR 989,202SAR 910,827SAR 2.0m
Net incomeSAR 703,496SAR 115,966SAR 165,740SAR 10,128SAR 79,648SAR 606,320SAR 717,246SAR 1.3m
Diluted earnings per share0.460.080.110.010.050.400.470.85
Cash from operations—SAR 2.0mSAR 1.0mSAR 3.0mSAR 2.0mSAR 3.0m—SAR 2.0m
Capital spending——−SAR 2.0m−SAR 1.0m−SAR 4.0m——−SAR 2.0m
Free cash flow——−SAR 1.0mSAR 2.0m−SAR 2.0m——SAR 0
Total assetsSAR 53.3mSAR 49.8mSAR 40.9mSAR 45.6mSAR 45.4mSAR 45.3mSAR 42.8m—
Cash and short-term investments—SAR 300,264SAR 767,107SAR 696,816SAR 700,398SAR 2.6mSAR 1.3m—
DebtSAR 1.0mSAR 5.4mSAR 5.8mSAR 3.0mSAR 3.1mSAR 2.1mSAR 2.0m—
Shareholders' equitySAR 23.5mSAR 22.7mSAR 22.6mSAR 22.4mSAR 22.4mSAR 23.0mSAR 23.6m—

Growth per year

Compound annual rate

3 years5 years10 years
Revenue12.4%——
Operating income-18.3%——
Net income-25.9%——

Average margins

Over each period

1 year3 years5 years10 years
Gross margin26.4%25.5%——

Valuation history

At each fiscal year end

FY2025FY2024FY2023
Price to earnings56.5—132.5
Price to sales0.61.51.5

Dividends and splits

Per share, in the currency the company pays

Paid for 0 years. Last went ex-dividend on 5 Sept 2023.

FY2023
Paid in the year0.39

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.